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ABSTRACT 
Acquired resistance to therapeutic agents is a major clinical concern in the 
prevention/treatment of malaria.  The parasite has developed resistance to specific 
drugs through two mechanisms: mutations in target proteins such as dihyfdrofolate 
reductase and bc1 complex for antifolates and nathoquiniones respectively and 
alterations in parasite transporter molecules such as p-glycoprotein homologue 1 
(Pgh1) and PfCRT.  Alterations in the expression of Pgh1 have been associated with 
modified susceptibility to a range of unrelated drugs.  The molecular mechanism(s) 
that are responsible for this phenotype are unknown.  We have shown previously (25) 
that the anticonvulsant phenobarbitone (PB) can induce reduced susceptibility to 
chloroquine (CQ) in Plasmodium falciparum, and in the current study we provide the 
first evidence for a molecular mechanism underlying this phenomenon.  We 
demonstrate that pre-treatment with PB can elicit decreased susceptibility to CQ in 
both CQ-resistant and CQ-sensitive parasite lines, and that this is associated with 
increased expression of the drug transporter Pgh1, but not PfCRT a gene product 
correlated with overt CQ resistance.  Furthermore we have investigated the proximal 
promoter regions from both pfmdr1 and pfcrt, and identified a number of putative 
binding sites for nuclear receptors with sequence similarities to regions known to be 
activated by phenobarbitone in mammals.  Whole genome analysis has revealed a 
putative nuclear receptor gene, providing the first evidence that nuclear-receptor 
mediated responses to drug exposure may be a mechanism of gene regulation in 
Plasmodium falciparum. 
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INTRODUCTION 
 Malaria remains one of the largest global health problems with between 1-2 
million deaths each year mostly in young African children. One of the greatest 
challenges facing Africa and the rest of the world in the fight against malaria is drug 
resistance, a problem that has reduced our armoury of effective drugs to a critically 
small number.  Chloroquine (CQ), the most widely used anti-malarial drug for many 
decades is now essentially useless with resistance being reported in all malaria 
endemic regions; indeed, it has been reported that CQ resistance (CQR) is a major 
factor behind the increasing burden of malaria worldwide (10).  Recent studies have 
implicated two genes in antimalarial drug resistance, pfcrt, which has been shown to 
confer resistance to CQ as well as a range of diverse structurally unrelated 
antimalarials (7, 8, 17, 21) and pfmdr1 which has been shown as a modulator of CQR 
and the basis of resistance to the quinoline methanols and related structures (28, 29, 
34, 52). 
 The pfcrt gene is highly polymorphic showing sequence variation at 15 
positions; interestingly a lysine to threonine substitution at codon 76 (K76T) is 
present in all CQR isolates identified to date.  Independent genetic experiments have 
confirmed the importance of mutations and in particular the K76T mutation in pfcrt as 
being responsible for the verapamil sensitive element of the CQ resistance phenotype 
(21, 43).  Furthermore, genetic manipulation of the expression level of PfCRT in a 
CQR parasite was shown to correlate with an increased susceptibility to CQ, 
presumably due to a reduced transport of drug through PfCRT (49).  Despite this 
correlation between PfCRT expression level and antimalarial drug susceptibility no 
evidence of altered expression of PfCRT has been identified in field isolates of P. 
falciparum (5). 
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 The P. falciparum P-glycoprotein homologue protein (Pgh1) encoded for by 
pfmdr1 was identified over a decade before pfcrt (20).  Like pfcrt, there are a number 
of mutations in pfmdr1 that have been associated with multi-drug resistance (8).  
However, despite these earlier correlations with CQR, recent genetic studies have 
shown that these mutations exert a greater influence on parasite susceptibility to a 
range of other antimalarials including mefloquine, halofantrine and artemisinin than 
they do for CQ susceptibility (34, 41, 42). 
 The multi-drug resistant phenotype in mammalian tumour cells involves the 
amplification of MDR genes and subsequent over expression of P-glycoprotein (3, 6).  
Studies in P. falciparum focused on this phenomenon and noted a correlation between 
pfmdr1 expression and CQR (8).  However, a number of further studies failed to 
corroborate this observation and since then it has been conclusively demonstrated that 
pfmdr1 copy number and expression of Pgh1 is more tightly associated with 
resistance to mefloquine than it is to CQR in field isolates and drug pressured 
laboratory lines (8, 27, 30, 31). 
 The molecular processes that govern the changes in pfmdr1 and pfcrt 
expression described above are poorly understood with little known about the role of 
promoters, terminators and transcription factors in the regulation of gene expression.  
P. falciparum promoters appear to conform to the classical eukaryotic bipartite 
structure consisting of a proximal promoter regulated by upstream enhancer elements 
(cis-acting elements)(15), yet a classical regulatory motif, which can be identified in 
multiple unrelated genes, has yet to be identified (24).  In stark contrast is the wealth 
of information available about the role of transcription factors and promoters in gene 
regulation in mammals:  One such example is the regulation of Phase I and II drug 
metabolizing enzymes and drug transporters by members of the nuclear receptor 
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super-family, such as PXR and CAR, and their role in modulating drug resistance 
patterns in mammals (19, 22).  The nuclear receptor superfamily comprises 48 
members in man, and acts within a hierarchical structure to co-ordinate body 
responses to a wide range of therapeutics, including antivirals, antifungals and 
antibiotics, are ligands for these receptors (1, 54) . 
 P. falciparum is known to possess orthologues for several nuclear receptor 
target genes, including CYPs, Pgp and MRP and previous work in our laboratory has 
shown that pre-treatment of parasite cultures with phenobarbitone, a potent inducer of 
CYPs and Pgp, resulted in a decreased susceptibility to CQ (26).  However, at the 
time of the initial observation the molecular processes that regulate drug induced 
changes in gene expression were unknown.  We propose a novel system of nuclear 
receptor inducible gene regulation based on the extensively characterized human 
system that includes drug activation of nuclear receptors, subsequent translocation to 
the nucleus, resulting in the increased rate of transcription mediated by RNA 
polymerases and subsequent increase in transporter protein levels.  
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MATERIALS AND METHODS 
P. falciparum Strains  
K1 (Thailand), a parasite isolate with a classical CQR phenotype and genotype 
was kindly donated by Professor D. Walliker (University of Edinburgh) and was 
cloned twice by the method of limiting dilution (37) to give the CQR clone, K1H6/2.  
K1HF and K1AM are halofantrine and amantadine resistant parasite lines 
respectively, selected from the CQR isolate K1H6/2 (17, 36).  Parasites were 
maintained in continuous culture.  Cultures contained a 2% suspension of O+ 
erythrocytes in RPMI 1640 (R8758) medium supplemented with 10% pooled human 
AB serum, 25 mM HEPES (pH 7.4), and 20 µM gentamicin sulphate (48). 
 
Pre-treatment with phenobarbitone  
Syncronized ring-stage cultures of P. falciparum parasites were exposed to 
0.1µM of phenobarbitone (PB) for a total period of 48h.  Parasites were washed twice 
with drug free RPMI 1640 medium to remove traces of PB and samples were 
processed for in vitro drug susceptibility testing.  To determine the effect of PB 
treatment on protein expression trophozoite stage parasites were exposed to 0.1µM of 
phenobarbitone (PB) for a total period of 48h and processed as described below. 
 
In vitro drug susceptibility assays 
 The effect of PB pre-treatment on CQ sensitivity in the absence of presence of 
5µM verapamil was determined from the incorporation of [3H]-hypoxanthine into 
parasite nucleic acids (4).  IC50 values were calculated for each assay using the four 
parameter logistic method (Grafit program, Erithacus software; Surrey, UK). 
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Analysis of Pgh1 and PfCRT expression. 
Suspensions of trophozoite parasites at 10-15% parasitaemia were isolated using 
saponin lysis, washed twice in ice cold PBS to remove cell debris and haemoglobin 
and re-suspended in ice cold PBS.  A series of liquid nitrogen freeze/thaw cycles was 
performed to ensure sufficient cell lysis.  The protein content of each sample was 
determined by the modified Bradford Assay (BIORAD, UK).  In order to normalise 
for loading each sample was diluted appropriately with PBS to give the same protein 
concentration before an equal volume of 2X SDS-PAGE loading buffer (125mM Tris-
Cl pH 6.8; 4% (w/v) SDS; 20% (v/v) glycerol; 10% (w/v) 2-mercaptoethanol; 0.02% 
(w/v) bromophenol blue) was added.  The samples were mixed vigorously with the 
2X SDS-PAGE loading buffer and boiled at 60°C for 15min.  Equal amounts of 
parasite protein from control and drug treated cultures were loaded onto a 4-15% 
gradient SDS-polyacrylamide gel and electroblotted onto PVDF membrane.  Protein 
expression was assessed by immunoblotting using antibodies raised against either the 
C-terminus of PfCRT or the N-terminus of Pgh1 which were controlled for loading 
using α-HSP70 antibodies.  Immunoreactive bands were visualised by Enhanced 
Chemiluminescence (ECL; Pharmacia Biotech, UK) and analysed by densitometry 
using the GeneTools software (Syngene, UK). 
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RESULTS 
In vitro sensitivity testing 
Pre-treatment with PB resulted in a decreased susceptibility to CQ in all 
parasite lines tested (figure 1).  Interestingly, the two drug-selected parasites, K1AM 
and K1HF, also exhibited a decreased susceptibility to CQ and had a partial return of 
the VP-sensitive CQR phenotype (figure 1).  This observation is unique and 
unexpected considering that the drug-selected parasite lines had lost the VP-sensitive 
CQR phenotype on selection for resistance to AM and HF respectively (17).  The 
observation that pre-treatment with PB results in an increased resistance to CQ 
confirm the observation of Ndifor et al., (25, 26). 
 
Effect of phenobarbitone on Pgh1 and PfCRT expression. 
Pre-treatment with PB resulted in a marked increase in the expression of Pgh1, 
the protein product of pfmdr1, in all parasite lines tested (figure 2A and 2B).  Pgh1 
expression was most pronounced in the halofantrine-resistant line, K1HF compared to 
the control K1H6/2 and the amantadine-resistant line, K1AM; Semi-quantitative 
measurements indicate a 6.4-fold vs 4.7-fold vs 5.4-fold increases in Pgh1 expression 
respectively.  However, PB treatment had no effect on the protein expression level of 
PfCRT in the lines tested (figure 2D and 2E). 
 
In silico search for transcription factors in 5’ UTR of pfmdr1 and pfcrt 
 Approximately 5kb of putative proximal promoter from pfmdr1 and pfcrt was 
examined for putative transcription factor binding sites using the MatInspector 
software (32). The MatInspector search matrix included transcription factors from 
vertebrates, insects, plants, fungi, nematodes and bacteria.  This approach, utilising a 
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matrix and core similarity of 0.75 identified 1975 and 1798 putative transcription 
factor binding sites in the proximal promoter of pfmdr1 and pfcrt respectively with a 
large percentage of these hits corresponding to regulators of cell cycle and the control 
of gene expression.  A manual filter was then applied to the data set, limiting hits to 
those transcription factors known to be involved in the regulation of mammalian 
multi-drug resistance genes (MDR), multi-resistance proteins (MRP) and cytochrome 
P450 enzymes:  From this more refined analysis 8 and 10 putative transcription factor 
binding sites were identified in the pfmdr1 and pfcrt proximal promoter regions 
respectively.  Figure 3 depicts the position of these transcription factors relative to the 
transcription start site and the start codon of the gene.  Tables 1 and 2 show the 
consensus nucleotide binding sequences identified by MatInspector, the transcription 
factor commonly associated with binding at that site, plus details of the exact 
sequence identified and its similarity to the consensus.  
 Preliminary analysis of the predicted parasite proteome using NuReBaSe - 
NUclear REceptor dataBASE (http://www.ens-
lyon.fr/LBMC/laudet/nurebase/nurebase.html) revealed a number of putative proteins 
with between 20 - 36% amino acid identity to PPARg, RXR, RAR, mineralcorticoid 
receptor (MR) and hepatic nuclear factor 4 (HNF4a on chromosomes 2, 3, 4, 10, 11, 
12 and 13. 
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DISCUSSION 
The observation that the potent anticonvulsant phenobarbitone produces a shift 
in the susceptibility of P. falciparum parasites to CQ was first noted by Ndifor et al., 
(26).  The parasite lines chosen for this study were the parental K1H6/2 and the two 
drug selected isolates, K1AM and K1HF (17).  All three parasite lines have 
previously been extensively characterised both phenotypically and genotypically with 
the major difference between them being the acquisition of the novel S163R mutation 
in PfCRT and the return to CQ-sensitivity coupled with a loss of the VP-sensitive 
component in the K1AM and K1HF lines (17, 36).  However, pre-treatment of the 
parasites with 0.1µM PB had little effect on parasite viability and each isolate 
continued to grow in 0.1µM PB at similar proliferation rates compared to control 
parasite cultures (data not shown), yet in vitro sensitivity testing for CQ-susceptibility 
showed that all parasite isolates exhibited a marked decrease in the susceptibility to 
CQ following PB pre-treatment (figure 1). Furthermore the K1AM and K1HF lines 
displayed phenotypic characteristics of CQR including the return of a partial VP-
sensitive component of CQR (figure 1). This observation is made more interesting 
since the K1AM and K1HF parasites had been previously shown to have lost the VP-
sensitive component of CQR upon selection with amantadine or halofantrine- a trait 
typically associated with CQS parasite lines (7, 17, 21, 36, 43). 
Since the incubation time was insufficient to elicit a genotypic change in the 
parasite, the unique pattern of changes in CQ-susceptibility produced by PB treatment 
suggest an adaptive response to PB.  It is well known that PB induces the expression 
of CYPs and ABC transporter proteins in mammals via nuclear receptor dependent 
mechanisms (13, 14, 16, 19, 38-40, 46, 53).  The changes in CQ-susceptibility 
observed after PB treatment could feasibly be controlled by an increased metabolism 
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of CQ by CYPs, a hypothesis originally put forward by Ndifor et al., (25, 26).  
However, it has been shown that CQ is not metabolised by malarial parasites (33, 47).  
We propose an alternate explanation, in keeping with the known effects of PB in other 
systems, that PB influences CQ-susceptibility levels by regulating the expression of 
drug transporter genes such as pfmdr1 and pfcrt, reducing the intracellular availability 
of CQ due to increased intracellular drug clearance.  Such a hypothesis is supported 
by the similarity of Pgh1 with mammalian Pgp’s, with Pgh1 a likely evolutionary 
antecedent of these mammalian proteins.  
Western blot analysis after treatment of parasites with PB resulted in a marked 
increase in the expression of the P. falciparum ABC transporter, Pgh1 compared to 
the un-treated controls in all parasite lines tested (figure 2).  PB had the most 
pronounced effect on Pgh1 expression in the parent clone, K1H6/2 and the 
halofantrine resistant isolate, K1HF with all lines showing at least a 3-fold increase in 
protein expression (figure 2).  Interestingly PB treatment had no effect on the 
expression of PfCRT with all parasite lines showing similar protein levels.  This 
observation strongly implicates the increased expression of Pgh1 in K1H6/2, K1AM 
and K1HF as being responsible for the decreased CQ-susceptibility and suggests a 
molecular link between these phenotypes. 
The increased expression of Pgh1 by PB in P. falciparum could be rationalised 
based on the accepted mechanisms for xenobiotic–mediated increases in drug 
transporter expression seen in mammals under the influence of the same chemicals; 
the activation of ligand activated transcription factors such as members of the nuclear 
receptor superfamily (14, 19, 45, 51).  In mammals, this occurs via two distinct 
mechanisms.  First, ligands such as pregnenalone 16α carbonitrile (PCN) are able to 
bind to the ligand binding domain of the pregnane X receptor (PXR), which triggers 
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dissociation from cytosolic chaperones and nuclear translocation of the receptor 
resulting in transactivation of target genes (44).  Second, PB elicits phosphorylation of 
the constitutive androstane receptor (CAR) via a signal transduction mechanism 
initiated at the cell membrane, which results in activation of the receptor with the 
same result (35)(figure 4).  Importantly, many mammalian nuclear receptors bind to 
similar response elements.  For example PXR and CAR mediate induction of CYP3A 
(53), CYP2B6 (9) and ABCB1 (2) via the same ER-6, DR-4 and PBREM motifs and 
an ER 8 mediates induction of ABCC2 by PXR, CAR and FXR (18). With this in 
mind, we have utilised a bioinformatic approach to screen the 3’ regulatory regions of 
parasite transporter genes for putative nuclear receptor response elements. 
The pfmdr1 promoter sequence contains a total of two ligand-activated 
transcription factor (LA-TF) binding motifs that could conceivably be activated and 
increase the expression of Pgh1, these being the barbiturate-inducible element (Barbie 
box) and the PXR/RXR response element. It should be noted that there is unlikely to 
be direct orthologues for PXR and CAR in plasmodium, as current evidence suggests 
that these two nuclear receptors diverged from a single ancestral gene at some point 
after the aves/mammalian split (310 Million years ago).  It is instead likely that the 
nuclear receptor concerned is an antecedent of the chicken CXR, with potentially a 
more generalized role in the response to xenobiotics in these organisms. Such a 
hypothesis is consistent with the promiscuity of mammalian drug response systems, 
with PB able to activate either the Barbie box (via ligand binding to the constitutive 
androstane receptor) the PXR/RXR motif (via ligand binding to PXR), both of which 
can result in the increased transcription and translation of mammalian Pgp (50, 53).  
Similarly, once ligand binding has occurred, CAR can bind to the PXR DNA binding 
domain and vice versa (53). 
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The experiments contained herein suggest the involvement of LA-TF’s in the 
regulation of Pgh1 expression, and hence the PB-mediated CQ-resistance of 
P.falciparum.  To date no LA-TFs have been identified in P. falciparum, but evidence 
does exist to suggest that primitive organisms may express members of the nuclear 
receptor superfamily: In C. elegans, a number of NR homologues have been 
identified, including NHR-8, which appears to share several characteristics with PXR 
and CAR (23).  NHR-8 is thought to function as a ‘xenobiotic sensor’ regulating the 
gene expression of C. elegans CYPs and the Pgp homologue, pgp-3; indeed, it has 
been suggested as the direct antecedent of chicken CXR, and hence mammalian 
PXR/CAR (12).  Interestingly, Lindblom postulate that CQ could be a ligand for 
NHR-8 resulting in changes in CYP or pgp-3 expression that results in a decreased 
susceptibility of C.elegans to CQ (23).  In fact a recent study by Gunasekera et al., 
(11) showed that the P. falciparum genome has the capacity to respond to external 
stimuli by identifying a number of loci that had altered gene expression after exposure 
to CQ including the pfmdr1 locus:  These findings corroborate the observations 
presented in this study and highlights the diversity of the LA-TF superfamily across 
species. Our proteome scan for putative nuclear receptors support such a hypothesis, 
identifying seven putative nuclear receptors, including potential orthologues for 
PPAR and the ubiquitous heterodimer partner RXR. 
This study provides the first evidence of a malarial parasite drug-inducible 
system of gene expression that is closely related to the mechanism used in a range of 
evolutionary diverse classes, including mammalia, aves and chromadorea.  Despite 
these strong similarities there are a number of components of the system that have not 
been identified in the malaria parasite and in order to validate this system these need 
to be identified and characterised (figure 4).  However, we propose that the induction 
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of Pgh1 observed after PB treatment is a direct cellular response to the drug in an 
attempt by the parasite to remove the drug thereby preventing toxicity.  The fact that 
the increased expression of Pgh1 was associated with an increased resistance to CQ 
further adds support for the role of this protein in conferring reduced parasite 
susceptibility to this important antimalarial.  Furthermore a preliminary analysis of the 
predicted parasite proteome using NuReBaSe - NUclear REceptor dataBASE 
(http://www.ens-lyon.fr/LBMC/laudet/nurebase/nurebase.html) revealed a number of 
putative proteins with between 20 - 36% amino acid identity to PPARg, RXR, RAR, 
mineralcorticoid receptor (MR) and hepatic nuclear factor 4 (HNF4a on chromosomes 
2, 3, 4, 10, 11, 12 and 13.  Cloning and functional characterisation of these proteins 
with respect to PB–responsive induction of Pgh1 is now warranted and will provide 
further insight into the gene regulation mechanisms adopted by the parasite. 
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FIGURE LEGENDS 
Figure 1 Effect of pre-treatment with phenobarbitone on CQ-susceptibility in the CQ-
resistant K1H6/2 isolate and the CQS isolates K1AM and K1HF.  Representative 
dose/response graph of the K1H6/2 (a), K1AM (b) and K1HF (c) isolates to 
chloroquine in the absence and presence of 5 µM verapamil at 1% haematocrit and 
1% parasitaemia after pre-treatment for 48h with 0.1µM phenobarbitone (PB).  Data 
is presented as means ± SEM, where n=3. 
 
Figure 2 Effect of pre-treatment with phenobarbitone on expression of Pgh1 and 
PfCRT.  Densitometric analysis of Western blots enabled the expression levels of 
Pgh1 and PfCRT to be determined in un-treated controls (A, D) and PB treated 
samples (B, E) respectively.  Equal amounts of protein for each isolate were separated 
on a 4-15% gradient gel and the protein detected using antibodies raised against Pgh1 
(~ 160 kDa), PfCRT (~ 44 kDa) and HSP-70 (~ 70 kDa).  Bands were visualised by 
ECL and quantified by densitometry using the GeneTools software (Syngene, UK).  
Ratio of Pgh1/HSP-70 and PfCRT/HSP-70 was used as an indicator of changes in 
expression of Pgh1 and PfCRT after treatment compared to controls (C, F).  Data is 
presented as means ± SEM, where n=3.  Statistical significance (represented by **) 
compared to untreated controls, where p<0.05. 
 
Figure 3 Schematic representation of the location of putative transcription factor 
binding sites, predicted transcription start sites (arrow) and putative TATAA boxes in 
the 5’ promoter sequences of pfmdr1 and pfcrt as identified by interrogation of the 
MatInspector database (32).  Abbreviations used are; BARBIE, barbiturate inducible 
element; PRE, progesterone receptor binding site; RAR, related orphan receptor 
alpha2; PXR/RXR, pregnane X receptor/retinoic acid receptor half-site; CAR/RXR, 
constitutive androstane receptor/retinoic acid receptor half-site; AhR, aryl 
hydrocarbon receptor; GRE, glucocorticoid receptor; PPAR/RXR, peroxisome 
proliferators activated receptor/retinoic acid receptor half-site. 
 
Figure 4 Proposed hypothesis for the inducible regulation of gene expression by 
phenobarbitone (PB) in P. falciparum.  (A) The molecular and cellular effects of PB 
in humans have been extensively characterised.  PB enters the cell and activates the 
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constitutive androstane receptor (CAR) resulting in dephosphorylation of CAR which 
subsequently translocates to the nucleus. CAR heterodimerizes with RXR in the 
nucleus with the resulting complex interacting directly with the phenobarbitone 
response element (PBRE) in the promoter resulting in transactivation of the gene.  In 
humans this activation can result in the increased expression of drug transporters such 
as MDR1, MRP1 and BCRP.  (B) Proposed model for PB regulation of gene 
expression in malarial parasites.  PB enters the parasite and activates nuclear receptor 
1 presumably through dephosphorylation of the protein.  The activated NR1 
translocates to the nucleus forming a dimer with NR2 which subsequently binds to the 
PBRE resulting in an increased turnover of RNA polymerase and transcription of the 
gene.  The changes in Pgh1 observed after PB treatment suggest that pfmdr1 is a 
target for PB regulated gene expression with an additional candidate being the P. 
falciparum multi-resistance protein 1 gene, pfmrp1. 
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Table 1 Distribution of transcription factor binding sites in the promoters of 
pfmdr1 and pfcrt 
 
1Consensus binding sequence indicates the core nucleotides (uppercase and red) and 
the possibilities for nucleotide matches at other positions of the TF motif, where 
Y=pyrimidine (C&T), R= purine (A&G), W= weak (A&T), S= strong (G&C), K= 
keto (T&G) and N= any nucleotide.  Abbreviations: PPAR/RXR, peroxisome 
proliferators activated receptor/retinoic acid receptor half-site; AhR, aryl hydrocarbon 
receptor; RAR, related orphan receptor a-2; PXR/RXR, pregnane X receptor/retinoic 
acid receptor half-site; CAR/RXR, constitutive androstane receptor/retinoic acid 
receptor half-site. 
Transcription factor (TF) Consensus TF binding sequence1 pfmdr1 pfcrt
Cellular & viral TATA box elements nnstATAAAwrnnnnnn + +
Barbiturate inducible element atnnAAAGcngrngg + +
Progesterone receptor binding site nnrgnacnnknTGTTCTnn + +
PPAR/RXR heterodimers cwrawctTAGGnCAAAGGTCAn - +
AhR nuclear translocator homodimers nnnnnCACGTGnn - +
Glucocorticoid receptor nngGTACAannTGTYCTnn - +
RAR-orphan receptor α-2 nwawnnAGGTCAnnnnn + +
PXR halfsite/RXR receptor nnTGAACTynn + -
CAR/RXR heterodimer binding site nnTGAACTynn + -
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Table 2 DNA sequence and matrix similarity of transcription factors identified in pfmdr1 and pfcrt 
1
 Core similarity is the match against the nucleotides representing the core motif of the TF, where 1= 100% identity 
2
 Matrix similarity is the overall similarity to the TF binding motif, where 1= 100% identity 
3
 Actual DNA sequence from either the pfmdr1 or pfcrt promoter with the nucleotides in red representing critical residues for binding 
 
Transcription factor (TF) Core Similarity1 Matrix Similarity2 DNA sequence3
Barbiturate inducible element 1 0.90 atgaAAAGgaaaaggg
Barbiturate inducible element 1 0.88 ttaaAAAGttgaaag
Barbiturate inducible element 1 0.89 atggAAAGgagagga
Progesterone receptor binding site 1 0.88 cttatccgaatTGTTcttc
Progesterone receptor binding site 1 0.90 tacgcaaaactTGTTctta
PXR halfsite/RXR receptor 1 0.98 gtTGAActtgt
RAR-orphan receptor a-2 1 0.93 agtaagaGGTCaagagg
Barbiturate inducible element 1 0.897 aaaaAAAGcagatga
Barbiturate inducible element 1 0.88 tttcAAAGcttgaag
Barbiturate inducible element 1 0.88 aggaAAAGgaaaagg
Glucocorticoid receptor 0.93 0.89 gttttacatattGTCCtga
Progesterone receptor binding site 1 0.89 tatcatcatttTGTTcttg
AhR nuclear translocator homodimers 1 0.90 ttagcaaCGTGtt
PPAR/RXR heterodimers 1 0.74 aaaaaagatgcaaaagatcaa
PPAR/RXR heterodimers 1 0.75 caaaatgatgatAAAGatcaa
RAR-orphan receptor a-2 0.75 0.832 ataattgGGTAaattgt
pfmdr1
pfcrt
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FIGURE 3 
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